In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indalo Therapeutics Inc.

www.antegrin.com

Latest From Indalo Therapeutics Inc.

Deals Shaping The Medical Industry, November 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.

Deals Market Intelligence

Deal Watch: Novartis, Cerulean Team To Develop Nanoparticle-Drug Conjugates

Leveraging the brain power behind the first approved IPF drug, Esbriet, small companies Antegrin and Cascadia merge to form the fibrosis-centered Indalo Therapeutics. Gedeon Richter in-licenses a biosimilar of Roche’s Herceptin.

Deals M & A

Tech Transfer Deals, May 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced March through April 2016.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Antegrin Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Indalo Therapeutics Inc.
  • Senior Management
  • Robert Jacks, Pres. & CEO
    George H Capps, VP & Head, Bus. Ops.
    Williamson Z Bradford, MD, PhD, CMO
    Scott D Seiwert, PhD, CSO
  • Contact Info
  • Indalo Therapeutics Inc.
    4320 Forest Park Ave., Ste. 304
    St. Louis, MO 63108
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register